Lucid Diagnostics Earnings Call Balances Progress, Pressure

Lucid Diagnostics Inc. ((LUCD)) has held its Q1 earnings call. Read on for the main highlights of the call.

Lucid Diagnostics’ latest earnings call painted a cautiously optimistic picture, with strong operational traction offset by stubborn reimbursement and cash-collection headwinds. Management highlighted growing test demand and an extended cash runway but acknowledged that delays in Medicare coverage and volatile adjudications still cloud the near-term financial outlook.

Test Volumes Exceed Pre-Medicare Targets

Lucid ran 3,177 EsoGuard tests in Q1 2026, described as almost 3,200, topping its stated pre-Medicare target range of 2,500 to 3,000 tests. While volumes slipped sequentially from Q4’s 3,664 tests, management stressed that demand remains robust relative to internal goals ahead of broad Medicare coverage.

Gap Between Billable Value and Recognized Revenue

At list price of $27.49 per test, Q1 billable value exceeded $8.7 million, roughly $9.0 million, yet recognized revenue was only $1.3 million or about 14% of billable. This disconnect underscores how current reimbursement uncertainty and strict accounting are masking the underlying economic potential of the growing test base.

Balance Sheet Fortified, Runway Into 2027

The company completed an underwritten public offering that raised about $16.8 million, lifting cash from $27.9 million at March 31 to roughly $44.8 to $45 million pro forma. Management said this capital extends Lucid’s operating runway into 2027, providing time to resolve reimbursement issues and scale commercial efforts.

VA Contract Opens a Large Federal Channel

Lucid secured a Federal Supply Schedule contract at a rate equal to the Medicare level of $1,938 per test and has already received an initial purchase order. The Veterans Health Administration represents an addressable population of approximately 9 million veterans, positioning the company for a potentially meaningful new revenue stream.

First Laboratory Benefit Manager Policy in Place

The company obtained its first positive coverage policy from a laboratory benefit manager, with public announcement expected in the coming weeks. Management believes this decision could influence downstream commercial payer policies and gradually expand reimbursed access for EsoGuard testing.

Operating Expenses Held in Check

Non-GAAP operating expenses were $11.7 million in Q1, roughly 2.5% below the five-quarter average of $12.0 million, reflecting disciplined cost control. Total operating expenses were flat year over year, and sequential OpEx fell about $2.0 million versus Q4, helped by lower G&A and the absence of one-time items.

Non-GAAP Loss Per Share Trend Improving

Non-GAAP net loss per share came in at $0.07, an improvement of around $0.03 compared with each of the prior three quarters. Management emphasized that this trend, combined with stable OpEx, shows the P&L is moving in the right direction even before full reimbursement normalization.

Clinical Momentum and Guideline Recognition

Lucid described its presence at the Digestive Disease Week conference as its best ever, citing strong physician interest. Importantly, an American Gastroenterological Association draft guideline preview cited EsoGuard and EsoCheck by name with high certainty evidence, which could drive future clinical adoption and payer engagement.

Revenue Recognition Constrained by ASC 606

Because EsoGuard remains in a transitional reimbursement phase and collection history is not fully predictable, the company recognizes most revenue only when cash is collected. Under ASC 606, this conservative approach drove recognized revenue down to about 14% of billable value, leaving reported sales well below the tests’ nominal economics.

Medicare LCD Delays Add Strategic Uncertainty

The Medicare local coverage determination process is facing logistical delays, and Lucid does not yet have a firm timetable for a final decision. Management reiterated that Medicare coverage would impact an estimated 40 to 50% of the addressable patient population, making the timing of an LCD a major swing factor for the business.

Collections and Adjudication Remain Volatile

Of Q1 claims submitted, about 77% had been adjudicated by the time of the call and 23% were still pending, with only roughly 31% of adjudicated claims yielding an allowable payment. The average allowed payment was around $1,646 per test, but many denials cited medical necessity, investigational labeling, prior authorization and noncovered status, highlighting inconsistent payer behavior.

High Cash Burn and Interest Costs Weigh on Fundamentals

Average quarterly cash burn including interest was $11.3 million over the last four quarters, rising to about $12.1 million in Q1 due to commercial investments. Lucid also carries a refinanced $22 million five-year note at 12% interest and recorded a $1.9 million other-income expense tied partly to a $1.2 million mark-to-market increase in the fair value of convertible notes.

VA Revenue Still Ahead, Not in Q1 Numbers

Despite the strategic win with the VA contract, there was no revenue contribution from this channel in Q1. The quarter’s activity centered on building a pipeline and securing purchase orders, with management expecting VA-related testing and revenue to emerge in subsequent periods.

Commercial Payer Progress Still Patchy

Commercial coverage remained mixed as some insurers appear to be waiting for Medicare’s decision before committing to broad policies. The company did not disclose covered-lives metrics, underscoring that commercial contracted coverage is still at an early stage despite constructive discussions and the upcoming LBM policy.

Share Count and Potential Dilution Overhang

GAAP shares outstanding at March 31 were 164.9 million, but management suggested investors use roughly 203 million shares for EPS modeling, inclusive of conversions and restricted awards. There are an additional 22.3 million advance shares that, if issued, could take the share count toward 225 million and add future dilution risk.

Seasonal Deductible Effects Distort Q1 Collections

Management noted that first-quarter collections are pressured by higher patient deductibles and co-pays, increasing volatility in cash receipts. These seasonal headwinds further complicate comparisons between billable value, recognized revenue and cash flow on a quarter-to-quarter basis.

Guidance and Management Outlook

For Q1, Lucid reiterated that it processed 3,177 EsoGuard tests with billable value above $8.7 million, recognized $1.3 million of revenue and saw about 72% of that revenue come from prior-period claims. The company expects its roughly $45 million in pro forma cash to fund operations into 2027 and remains confident in a positive Medicare LCD while it advances VA, LBM and health-system commercialization.

Lucid’s earnings call showcased a company winning on volume, clinical validation and balance-sheet extension but still constrained by reimbursement friction and high cash burn. Investors will likely focus on the timing of Medicare coverage, the ramp of VA and commercial contracts and the evolution of collections as the key determinants of when the business model can fully inflect.